OverviewSuggest Edit

4D Molecular Therapeutics is a biotechnology company focused on the creation of gene therapy products to cure genetic diseases. Its Therapeutic Vector Evolution platform enables to create adeno-associated virus (AAV) gene therapy vectors, which deliver genes to any diseased tissue or organ in the body.
TypePublic
Founded2013
HQEmeryville, CA, US
Website4dmoleculartherapeutics.com

Latest Updates

Employees (est.) (Sept 2020)78(+37%)
Job Openings25
Revenue (FY, 2020)$13.6 M(+95%)
Share Price (Nov 2021)$25
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at 4D Molecular Therapeutics

David Kirn

David Kirn

Chief Executive Officer, Co-Founder, President & Director
Robert Fishman

Robert Fishman

Chief Medical Officer
Peter Francis

Peter Francis

Chief Scientific Officer, Ophthalmology Therapeutic Area Head
Theresa Janke

Theresa Janke

Chief Strategy Officer & Co-Founder
Fred Kamal

Fred Kamal

Chief Operating Officer & Chief Technical Officer
August Moretti

August Moretti

Chief Financial Officer
Show more

4D Molecular Therapeutics Office Locations

4D Molecular Therapeutics has an office in Emeryville
Emeryville, CA, US (HQ)
5858 Horton St #455
Show all (1)

4D Molecular Therapeutics Financials and Metrics

4D Molecular Therapeutics Revenue

4D Molecular Therapeutics's revenue was reported to be $13.61 m in FY, 2020
USD

Revenue (Q1, 2021)

2.0m

Net income (Q1, 2021)

(16.4m)

EBIT (Q1, 2021)

(16.3m)

Market capitalization (12-Nov-2021)

668.5m

Closing stock price (12-Nov-2021)

25.0

Cash (31-Mar-2021)

259.9m
4D Molecular Therapeutics's current market capitalization is $668.5 m.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

5.8m14.1m7.0m13.6m

Revenue growth, %

144%(51%)

General and administrative expense

3.5m6.2m13.9m17.2m

R&D expense

13.6m18.4m43.9m53.0m
Half Year
USDH1, 2018H1, 2019

Revenue

5.1m4.4m

General and administrative expense

2.2m4.9m

R&D expense

8.2m17.0m

Operating expense total

10.4m21.9m
Quarterly
USDQ1, 2021

Revenue

2.0m

General and administrative expense

5.5m

R&D expense

12.8m

Operating expense total

18.3m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

23.9m91.8m49.7m276.7m

Accounts Receivable

321.0k1.1m978.0k1.5m

Prepaid Expenses

4.4m

Current Assets

24.5m94.1m52.5m282.7m
Quarterly
USDQ2, 2019Q3, 2020Q1, 2021

Cash

72.9m88.8m259.9m

Accounts Receivable

1.2m896.0k965.0k

Prepaid Expenses

3.7m

Current Assets

75.4m92.5m264.5m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(11.2m)(9.6m)(49.3m)(56.7m)

Depreciation and Amortization

626.0k697.0k1.0m1.4m

Accounts Payable

(114.0k)438.0k533.0k43.0k

Cash From Operating Activities

8.2m(16.3m)(36.7m)(50.9m)
Quarterly
USDQ2, 2018Q2, 2019Q3, 2019Q3, 2020Q1, 2021

Net Income

(5.2m)(16.5m)(33.2m)(36.1m)(16.4m)

Depreciation and Amortization

341.0k406.0k686.0k1.1m381.0k

Accounts Payable

559.0k62.0k(175.0k)(524.0k)(601.0k)

Cash From Operating Activities

(6.4m)(17.2m)(28.0m)(33.4m)(15.4m)
USDFY, 2017

Financial Leverage

-1.4 x
Show all financial metrics

4D Molecular Therapeutics Operating Metrics

Q2, 2019Q3, 2020

Lead Optimization Stage Products

3

IND-Enabling Stage Products

33

Phase I Trials Products

3
Show all operating metrics

4D Molecular Therapeutics Revenue Breakdown

Embed Graph

4D Molecular Therapeutics revenue breakdown by geographic segment: 90.0% from Switzerland, 9.5% from United States and 0.5% from Other

4D Molecular Therapeutics Online and Social Media Presence

Embed Graph

4D Molecular Therapeutics News and Updates

4D Molecular Therapeutics Announces Pricing of Public Offering of Common Stock

EMERYVILLE, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced today that it priced an underwritten public offering of 4,750,000 shares of …

4D Molecular Therapeutics Reports Interim Results from the 4D-310 Phase 1/2 Clinical Trial in Patients with Fabry Disease and Provides Clinical Data Update from the 4D-110 Phase 1/2 Clinical Trial in Patients with Choroideremia

- First-ever clinical activity data reported on 4D-310 Fabry disease product candidate utilizing the proprietary C102 targeted and evolved vector invented through Therapeutic Vector Evolution

4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150, a Dual-Transgene Intravitreal Gene Therapy for Patients with wet AMD

Initiation of 4D-150 Phase 1/2 clinical trial sites expected before year-end Initiation of 4D-150 Phase 1/2 clinical trial sites expected before year-end

4D Molecular Therapeutics Announces Late-Breaking Presentation of 4D-125 Clinical Data at the Upcoming ASRS Annual Meeting

EMERYVILLE, Calif., Sept. 24, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced a late-breaking presentation of preliminary clinical data from the on-going 4D-12…

4D Molecular Therapeutics Announces Rare Disease Ophthalmology Product Candidate Portfolio Update, Including Initial Clinical Safety and Tolerability Data for 4D-110 for Choroideremia and 4D-125 for XLRP, and Termination of Roche Collaboration and License Agreement

EMERYVILLE, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced an update on their rare disease ophthalmology product candidate portfolio includin…

4D Molecular Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

EMERYVILLE, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that management will participate in the Goldman Sachs 42nd Annual Global Healthcar…
Show more

4D Molecular Therapeutics Blogs

A Targeted AAV Gene Therapy Product Candidate, 4D-310, for the Treatment of Fabry Disease: Intravenous Biodistribution, Transgene Expression & Safety in Non-Human Primates

Kevin Wittlesey, et al. Presented at the 24th Annual American Society of Gene & Cell Therapy (ASGCT) Meeting, May 11-14, 2021. The post A Targeted AAV Gene Therapy Product Candidate, 4D-310, for the Treatment of Fabry Disease: Intravenous Biodistribution, Transgene Expression & Safety in Non…

A Multi-Mechanistic Anti-Angiogenic AAV Gene Therapy Product Candidate, 4D-150, for the Treatment of Wet Age-Related Macular Degeneration (Wet AMD) and Diabetic Macular Edema (DME): Intravitreal Biodistribution, Transgene Expression, Safety and Efficacy in Non-Human Primates

Peter Francis, et al. Presented at the 24th Annual American Society of Gene & Cell Therapy (ASGCT) Meeting, May 11-14, 2021. The post A Multi-Mechanistic Anti-Angiogenic AAV Gene Therapy Product Candidate, 4D-150, for the Treatment of Wet Age-Related Macular Degeneration (Wet AMD) and Diabetic M…

Identification and Characterization of a Novel AAV Capsid & Product for the Treatment of Cystic Fibrosis Lung Disease

Melissa A. Calton, et al. Presented at the American Thoracic Society (ATS) 2021 Virtual Conference, May 14-19, 2021. The post Identification and Characterization of a Novel AAV Capsid & Product for the Treatment of Cystic Fibrosis Lung Disease appeared first on 4D Molecular Therapeutics.

4D Molecular Therapeutics Strengthens Leadership Team with Key Appointments in Clinical Research and Development

Emeryville, CA – December 2, 2020 – 4D Molecular Therapeutics (4DMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that Robert Fishman, M.D. has joined as Chief Medical Officer & Therapeutic Area Head, Pulmonology; Raphae…

4D Molecular Therapeutics Appoints Nancy Miller-Rich and Shawn Tomasello to its Board of Directors

Emeryville, CA – November 18, 2020 – 4D Molecular Therapeutics (4DMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced the appointment of Nancy Miller-Rich and Shawn Tomasello to the Board of Directors. Nancy Miller-Rich brings …

4D Molecular Therapeutics Frequently Asked Questions

  • When was 4D Molecular Therapeutics founded?

    4D Molecular Therapeutics was founded in 2013.

  • Who are 4D Molecular Therapeutics key executives?

    4D Molecular Therapeutics's key executives are David Kirn, Robert Fishman and Peter Francis.

  • How many employees does 4D Molecular Therapeutics have?

    4D Molecular Therapeutics has 78 employees.

  • What is 4D Molecular Therapeutics revenue?

    Latest 4D Molecular Therapeutics annual revenue is $13.6 m.

  • What is 4D Molecular Therapeutics revenue per employee?

    Latest 4D Molecular Therapeutics revenue per employee is $174.5 k.

  • Who are 4D Molecular Therapeutics competitors?

    Competitors of 4D Molecular Therapeutics include Vertex Pharmaceuticals, Intellia Therapeutics and Verogen.

  • Where is 4D Molecular Therapeutics headquarters?

    4D Molecular Therapeutics headquarters is located at 5858 Horton St #455, Emeryville.

  • Where are 4D Molecular Therapeutics offices?

    4D Molecular Therapeutics has an office in Emeryville.

  • How many offices does 4D Molecular Therapeutics have?

    4D Molecular Therapeutics has 1 office.